Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics

Posted on
by

Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics
The Key Diabetic Gastroparesis Companies in the market include – CINRx Pharma, Vanda Pharmaceuticals, Dr. Falk Pharma, and others.

Diabetic Gastroparesis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Theravance Biopharma, Eli Lilly and Company, Processa Pharmaceuticals, PTC Therapeutics

DelveInsight’s “Diabetic Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of Diabetic Gastroparesis, historical and forecasted epidemiology as well as the Diabetic Gastroparesis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

To Know in detail about the Diabetic Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Gastroparesis Market Forecast

 

Some of the key facts of the Diabetic Gastroparesis Market Report: 

  • The market size of Diabetic Gastroparesis was estimated to be ~USD 1,970 Million in the year 2023 and is expected to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, The US Food and Drug Administration (FDA) rejected the new drug application (NDA) from Vanda Pharmaceuticals for tradipitant intended for treating symptoms of gastroparesis. This decision was conveyed in a complete response letter (CRL).

  • In May 2024, CinDome Pharma, a CinRx portfolio company focused on developing safe, long-term treatments for gastroparesis, announced a $40 million extension to its Series B financing. This addition from existing investors, including Perceptive Advisors and CinRx Pharma, brings the total Series B funding to $59 million. The funds will be used to advance the enrollment and evaluation of deudomperidone in the Phase 2 envision3D study for adults with diabetic gastroparesis, as well as to prepare the company for future registrational trials.

  • In 2023, Germany recorded the largest market size among the EU4 and the UK, totaling around USD 225 million, followed by the UK, while Spain had the smallest market size.

  • According to estimates from DelveInsight, the total number of prevalent cases of Diabetic Gastroparesis in the 7MM was 14,950,000 in 2023, and this figure is expected to increase by 2034.

  • In 2023, the EU4 and the UK represented around 32% of the total prevalent cases of Diabetic Gastroparesis.

  • In 2023, approximately 40% of diabetic gastroparesis cases in the United States were linked to Type 1 diabetes. Patients with Type 1 diabetes are more often impacted by gastroparesis due to extended periods of high blood glucose levels, resulting in nerve damage, especially to the vagus nerve, which regulates stomach function.

  • In 2023, the United States exhibited the highest prevalence of diabetic gastroparesis among the seven major markets (7MM), with 85% of these cases undergoing treatment.

  • Key Diabetic Gastroparesis Companies: CINRx Pharma, Vanda Pharmaceuticals, Dr. Falk Pharma, and others.

  • Key Diabetic Gastroparesis  Therapies: CIN-102, Tradipitant, Naronapride, and others

  • The Diabetic Gastroparesis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Gastroparesis pipeline products will significantly revolutionize the Diabetic Gastroparesis market dynamics.

 

Diabetic Gastroparesis Overview: 

Diabetic Gastroparesis is a condition characterized by delayed gastric emptying, which often occurs in individuals with diabetes. It is caused by nerve damage, particularly to the vagus nerve, which controls the muscles of the stomach. Symptoms can include nausea, vomiting, bloating, abdominal pain, and difficulty in controlling blood sugar levels. This delayed emptying can lead to poor digestion and nutrient absorption, making it challenging for patients to manage their diabetes effectively. Treatment options may include dietary changes, medications to stimulate gastric motility, and, in severe cases, interventions like gastric electrical stimulation.

 

Get a Free sample for the Diabetic Gastroparesis Market Report:

https://www.delveinsight.com/report-store/diabetic-gastroparesis-market-size

 

Diabetic Gastroparesis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Diabetic Gastroparesis Epidemiology Segmentation:

The Diabetic Gastroparesis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Diabetic Gastroparesis

  • Prevalent Cases of Diabetic Gastroparesis by severity

  • Gender-specific Prevalence of Diabetic Gastroparesis

  • Diagnosed Cases of Episodic and Chronic Diabetic Gastroparesis

 

Download the report to understand which factors are driving Diabetic Gastroparesis epidemiology trends @ Diabetic Gastroparesis Epidemiology Forecast

 

Diabetic Gastroparesis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Gastroparesis market or expected to get launched during the study period. The analysis covers Diabetic Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Diabetic Gastroparesis Therapies and Key Companies

  • CIN-102: CINRx Pharma

  • Tradipitant: Vanda Pharmaceuticals

  • Naronapride: Dr. Falk Pharma

 

Discover more about therapies set to grab major Diabetic Gastroparesis market share @ Diabetic Gastroparesis Treatment Market

 

Scope of the Diabetic Gastroparesis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Diabetic Gastroparesis Companies: CINRx Pharma, Vanda Pharmaceuticals, Dr. Falk Pharma, and others

  • Key Diabetic Gastroparesis Therapies: CIN-102, Tradipitant, Naronapride, and others

  • Diabetic Gastroparesis Therapeutic Assessment: Diabetic Gastroparesis current marketed and Diabetic Gastroparesis emerging therapies

  • Diabetic Gastroparesis Market Dynamics: Diabetic Gastroparesis market drivers and Diabetic Gastroparesis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Diabetic Gastroparesis Unmet Needs, KOL’s views, Analyst’s views, Diabetic Gastroparesis Market Access and Reimbursement 

 

To know more about Diabetic Gastroparesis companies working in the treatment market, visit @ Diabetic Gastroparesis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Diabetic Gastroparesis Market Report Introduction

2. Executive Summary

3. SWOT analysis

4. Diabetic Gastroparesis Patient Share (%) Overview at a Glance

5. Diabetic Gastroparesis Market Overview at a Glance

6. Diabetic Gastroparesis Disease Background and Overview

7. Diabetic Gastroparesis Epidemiology and Patient Population

8. Country-Specific Patient Population of Diabetic Gastroparesis 

9. Diabetic Gastroparesis Current Treatment and Medical Practices

10. Diabetic Gastroparesis Unmet Needs

11. Diabetic Gastroparesis Emerging Therapies

12. Diabetic Gastroparesis Market Outlook

13. Country-Wise Diabetic Gastroparesis Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Diabetic Gastroparesis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/